MicroRNA 30e (miR-30e)

MicroRNA 30e (miR-30e) is a short, non-coding RNA molecule classified as a microRNA and encoded by the MIR30E gene in humans. It functions principally as a post-transcriptional regulator of gene expression by binding to the 3' untranslated regions (3' UTR) of target mRNAs, thereby modulating their stability and translation. miR-30e plays crucial regulatory roles in multiple biological and pathological processes, including inhibition of cell proliferation and invasion in cancer; suppression of tumor growth mostly by targeting mRNAs like IRS1 and androgen receptor (AR); regulation of oxidative stress and reactive oxygen species in vascular disease by modulating TGF-β-mediated NADPH oxidase 4 signaling pathways; and involvement in processes such as apoptosis, cell cycle control, and fibrosis[1][2][4][6]. Altered miR-30e expression is associated with diverse diseases—including various cancers (where its downregulation correlates with tumor aggressiveness and chemoresistance) and cardiovascular diseases such as atherosclerosis (where diminished miR-30e enhances oxidative stress and plaque instability)[1][2][4][6]. As a result, miR-30e is being explored as both a therapeutic target (mainly through nucleic acid-based therapeutics) and a biomarker for disease prognosis and patient selection, though clinical drug development is in early preclinical stages[2][4][6].

Other names

hsa-mir-30eMIR30EMIR30E*MIRN30Emir-30e*

Gene silencing via post-transcriptional mRNA targeting (e.g., IRS1, androgen receptor/AR, FBXO45, SRSF7, MYBL2, Snai1); Suppression of oncogenic signaling pathways (e.g., AKT, ERK1/2, HIF-1α/VEGF); Regulation of oxidative stress pathways (e.g., TGF-β/NADPH oxidase 4-dependent signaling via Snai1)